Photo from wikipedia
Circulating tumor DNA (ctDNA) is emerging as a versatile biomarker for noninvasive genotyping and response monitoring in specific B‐cell lymphomas; however, few studies have been conducted to explore ctDNA‐based mutation… Click to show full abstract
Circulating tumor DNA (ctDNA) is emerging as a versatile biomarker for noninvasive genotyping and response monitoring in specific B‐cell lymphomas; however, few studies have been conducted to explore ctDNA‐based mutation profiling across non‐Hodgkin lymphomas (NHLs) and genomic changes after initiation of chemotherapy.
Keywords:
circulating tumor;
tumor dna;
mutation;
non hodgkin;
mutation profiling
Journal Title: European Journal of Haematology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!